Incidence of respiratory syncytial virus infection in children with congenital heart disease undergoing immunoprophylaxis with palivizumab in Pará state, north region of Brazil.
Roseane Porfírio de SouzaAndre Luis Ribeiro RibeiroSílvio Augusto Fernandes de MenezesLuiz Fernando Almeida MachadoPublished in: BMC pediatrics (2019)
Although the lack of a control group doesn't allow to affirm the effectiveness of HRSV passive immunization, the immunoprophylaxis with palivizumab appeared to be totally efficient in preventing respiratory infection by HRSV in children up to two years of age with CHD.